Atea Pharmaceuticals (NASDAQ:AVIR) Director Sells $72,095.40 in Stock

Atea Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Director Bruce Polsky sold 18,252 Atea shares for $72,095 at an average price of $3.95, leaving him with 158,580 shares. He also sold shares in the two preceding sessions.
  • Atea reported a quarterly loss of $0.40 per share, better than analysts’ $0.51 loss estimate. The stock traded at $3.99, within a 52-week range of $2.92 to $6.45.
  • Analysts’ average rating is Hold, with a consensus price target of $8.00; ratings range from Strong Buy to Sell.
  • Five stocks we like better than Atea Pharmaceuticals.

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Get Free Report) Director Bruce Polsky sold 18,252 shares of the firm's stock in a transaction that occurred on Wednesday, November 18th. The shares were sold at an average price of $3.95, for a total transaction of $72,095.40. Following the completion of the transaction, the director directly owned 158,580 shares of the company's stock, valued at $626,391. This represents a 10.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Bruce Polsky also recently made the following trade(s):

  • On Monday, November 16th, Bruce Polsky sold 14,254 shares of Atea Pharmaceuticals stock. The stock was sold at an average price of $4.27, for a total transaction of $60,864.58.
  • On Tuesday, November 17th, Bruce Polsky sold 8,720 shares of Atea Pharmaceuticals stock. The stock was sold at an average price of $4.03, for a total value of $35,141.60.

Atea Pharmaceuticals Stock Performance

Shares of Atea Pharmaceuticals stock traded up $0.03 during trading hours on Wednesday, reaching $3.99. 342,250 shares of the company were exchanged, compared to its average volume of 307,434. The firm has a market cap of $320.40 million, a PE ratio of -2.05 and a beta of 0.76. Atea Pharmaceuticals, Inc. has a 1 year low of $2.92 and a 1 year high of $6.45. The stock's fifty day moving average is $4.70 and its 200 day moving average is $4.94.

Atea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) last released its earnings results on Monday, November 9th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.51) by $0.11. Research analysts expect that Atea Pharmaceuticals, Inc. will post -1.60 earnings per share for the current year.

Institutional Investors Weigh In On Atea Pharmaceuticals

Several institutional investors have recently modified their holdings of AVIR. BlackRock Inc. purchased a new stake in Atea Pharmaceuticals during the 2nd quarter worth about $40,548,000. Irenic Capital Management LP acquired a new position in shares of Atea Pharmaceuticals during the 1st quarter worth about $1,623,000. Hsbc Holdings PLC acquired a new position in shares of Atea Pharmaceuticals during the 2nd quarter worth about $1,023,000. Arrowstreet Capital Limited Partnership purchased a new position in shares of Atea Pharmaceuticals in the 1st quarter valued at about $1,133,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Atea Pharmaceuticals in the 2nd quarter valued at about $881,000. 86.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on AVIR shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Atea Pharmaceuticals in a research note on Thursday, October 15th. Morgan Stanley upped their target price on shares of Atea Pharmaceuticals from $7.00 to $8.00 and gave the stock an "equal weight" rating in a research note on Monday. Finally, Wall Street Zen raised shares of Atea Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday, September 12th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $8.00.

View Our Latest Stock Report on AVIR

About Atea Pharmaceuticals

(Get Free Report)

Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing oral antiviral medicines for serious viral diseases. Its research centers on compounds intended to interfere with viral replication. The company's investigational portfolio has included bemnifosbuvir, an oral antiviral candidate studied for COVID-19, as well as programs targeting other viral infections, including dengue. These medicines are investigational and are not established marketed treatments.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Atea Pharmaceuticals Right Now?

Before you consider Atea Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atea Pharmaceuticals wasn't on the list.

While Atea Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines